[go: up one dir, main page]

HK1006171B - Insulin derivatives, their use and a pharmaceutical composition containing same - Google Patents

Insulin derivatives, their use and a pharmaceutical composition containing same Download PDF

Info

Publication number
HK1006171B
HK1006171B HK98105250.7A HK98105250A HK1006171B HK 1006171 B HK1006171 B HK 1006171B HK 98105250 A HK98105250 A HK 98105250A HK 1006171 B HK1006171 B HK 1006171B
Authority
HK
Hong Kong
Prior art keywords
formula
insulin
insulin derivative
alkylamino
derivative
Prior art date
Application number
HK98105250.7A
Other languages
German (de)
French (fr)
Chinese (zh)
Other versions
HK1006171A1 (en
Inventor
Dorschug Michael
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE3837825A external-priority patent/DE3837825A1/en
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of HK1006171B publication Critical patent/HK1006171B/en
Publication of HK1006171A1 publication Critical patent/HK1006171A1/en

Links

Description

It is well known that insulin and insulin derivatives are required in significant quantities for the treatment of diabetes mellitus and are sometimes produced on a large scale.Despite the considerable number of existing insulin preparations and variations with different action profiles, there is still a need for further insulin products with different properties and action characteristics due to the diversity of organisms with their inter- and intra-individual variations.
For example, insulin derivatives with delayed action are described in EP-B-132 769 and EP-B-132 770. Other where R1 means H or H-Phe, R30 stands for the residue of a neutral, genetically coded L-amino acid and R31 is a physiologically sound organic group of basic character with up to 50 C atoms, which is composed of 0 to 3 α-amino acids and may have a free, ester, amide, lactone or CH2OH reduced terminal carboxyl function.
These insulin derivatives have an isoelectric point between 5.8 and 8.5 (as measured in isoelectric focus) and the isoelectric point, which is shifted into the neutral range relative to the isoelectric point of the unmodified native insulin or proinsulin (at pH = 5.4), is due to the additional positive charges on the surface of the molecule due to the basic modification, which makes these basically modified insulin derivatives less soluble in the neutral range than, for example, native insulin or proinsulin, which are normally soluble in the neutral range.
The delay or deposit effect of the basically modified insulin derivatives of formula I is due to their solubility at the isoelectric point. The resolution of the insulin derivatives under physiological conditions is to be achieved according to the two abovementioned formulae by cleaving the additional base groups, which, depending on the derivative, results in triptyl or trypsin-like and/or carboxypeptidase B-like and/or esterase activity. The cleavage groups are either purely physiological metabolites or readily metabolizable but physiologically harmless substances.
The above-mentioned principle of storage as a result of basic modification of insulin has been further exploited by the provision and corresponding use of other basically modified insulin derivatives, mainly within the A and B chains; see e.g. EP-A-0194 864 and EP-A-0254 516.
The insulin derivatives described in EP-A-0194 864 contain a basic amino acid at position B27 and/or a neutral amino acid at positions A4, A17, B13 and/or B21 and the C-terminal carboxyl group of the B-chain is blocked by an amide or ester residue.
The insulin derivatives according to EP-A-0254 516 are very similar to those according to the above-mentioned EP-A; however, in order to increase stability at the weak acid pH of the corresponding pharmaceutical preparations, the amino acid asn in position A21 can be replaced by other amino acids which are more stable in acidic media, such as Asp. Asn (= asparagine) differs from Asp (= asparagine acid) as is known by the blocking of one of the two carboxyl groups by the amide group: Other
Another modification of the insulin molecule in the A and B chains, in particular by replacing the amino acid His in the B10 position with zinc, which is responsible for the complex formation and thus has a certain delaying effect, is to produce rapidly acting insulin derivatives; see EP-A-0214 826.
All insulin derivatives according to the last three forms are mainly modified within the A and B chains and are produced by genetic engineering.
In the effort to increase the stability of the basically modified insulin derivatives at the C-terminal end of the B chain in acidic media, as described in the abovementioned EP patents EP-B-0132 769 and EP-B-0132 770, and to modify their action profile, if necessary, this objective has been found to be achieved in a favourable way. by substitution of Asn21 by other genetically coding amino acids not containing an amide group and, where appropriate, by substitution of HisB10 by other genetically coding amino acids.
The invention is therefore based on insulin derivatives of formula II Other in which R1H or H-Phe means,R2 means a genetically coded L-amino acid without an amide group,R30 means the rest of a neutral genetically coded L-amino acid,R31 means a physiologically safe organic group of up to 50 C-atoms of basic character, in which 0 to 3 α-amino acids are involved and where available the final carboxyl function may be free, as ester function, as amide function, as lactone or reduced to CH2OH, andX means a genetically coded L-amino acid with an isoelectric point between 5 and 8.5 and its physiologically compatible salts.
The new insulin derivatives and their physiologically compatible salts are stable over long periods at the low acid pH of corresponding pharmaceutical preparations and have a modified (shorter) action profile compared to the known unchanged basically modified insulin derivatives of formula I mentioned at the beginning, especially if HisB10 is still replaced by other amino acids.
In formula II, R1 is preferably H-Phe.
Genetically coded L-amino acids not containing an amide group - for R2 - are The following shall be added to the list of products: Gly, Ala, Ser, Thr, Asp and Glu, especially Asp, are preferred.
Neutral, genetically coded L-amino acids - for R30 - are Gly, Ala, Ser, Thr, Val, Leu, Ile, Asn, Gln, Cys, Met, Tyr, Phe and Pro, with Ala, Thr and Ser being preferred.
R31 is a physiologically safe organic group of basic characteristics with up to 50 C atoms, in the construction of which 0-3 α-amino acids are involved. Amino- ((C2-C6-) alkoxy, C1-C4) alkylamino- ((C2-C6) alkoxy, Di- ((C1-C4) alkylamino- ((C2-C6) alkoxy, Tri- ((C1-C4) ammonium- ((C2-C6) alkoxy, Amino- ((C2-C6) alkylamino, [ ((C1-C4) alkylamino- ((C2-C6) alkylamino, Di- ((C1-C4) alkylamino- ((C2-C6) alkylamino or [Tri- ((C1-C4) alkylamino]- ((C2-C6) alkylamino, in particular -O- ((CH2) p-O- (O- ((CH2) p-O- (CH2) p-NR3, -NH- (NH-NH-NR2) p-NH-NR2 or p-NH-R2 or R-NR3, or is a different substance and is equal to or equal to R-C1 or R-C2 or R-C4 or R-C1 or R-C2 or R-C4 or R-C2 or R-C4 or R-C1 or R-C2 or R-C2 or R-C2 or R-C2 or R-C2 or R-C2 or R-C2 or R2 or R-C2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2 or R2
If up to 3 α-amino acids are involved in the construction of R31, these are primarily neutral or basic naturally occurring L-amino acids and/or their corresponding D-amino acids. Neutral naturally occurring amino acids are in particular Gly, Ala, Ser, Thr, Val, Leu, Ile, Asn, Gln, Cys, Met, Tyr, Phe, Pro and Hyp. Basic naturally occurring amino acids are in particular Lys, Hyl, Orn, Cit and His. If only neutral α-amino acids are involved, their final carboxyl blocking function - R31 has a basic character - cannot be free; the carboxyl function must be much more in this case with a base group or a diethyl ester, whereby such groups are preferable to the base groups - in the case that neutral α-amino acids such as α-amino acids (C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-C1-
As a lactone, the final carboxyl function can of course only be present if the final amino acid is a hydroxy amino acid.
In addition, the final carboxyl function can also be reduced to CH2OH.
Preferably R31 consists of 1, 2 or 3 of the above basic naturally occurring amino acids; particularly R31 = Arg-OH or Arg-Arg-OH.
The same amino acids as for R2 are used as genetically coded L-amino acids for X, but the genetically coded L-amino acids containing an amide group - i.e. asn and gln - are also possible; the latter - asn and gln - are even preferred here.
Sequences (A1 - A20) and (B1 - B9, B11 - B29) are preferably human, porcine or bovine insulin sequences, in particular human insulin sequences.
Examples of insulin derivatives of formula II are:
The production of the insulin derivatives of formula II is mainly genetic engineering by site-directed mutagenesis using standard methods.
This is done by constructing a gene structure coding for the desired formula II insulin derivative and seeking expression in a host cell, preferably a bacterium such as E. coli or a yeast, in particular Saccharomyces cerevisiae, and, if the gene structure is coding for a fusion protein, releasing the formula II insulin derivative from the fusion protein; analogous methods are described, for example, in EP-A-0 211 299, EP-A-0 227 938, EP-A-0 229 998, EP-A-0 286 956 and DE patent application P 38 21 159.9 of 23 June 1988 (HOE 88/F 158).
The breakdown of the fusion protein component after cell excretion is carried out either chemically by halogen cyanide (see EP-A-0 180 920) or enzymatically by lysostaphin (see DE-A-37 39 347).
Err1:Expecting ',' delimiter: line 1 column 152 (char 151)
The C-peptide is removed by trypthic cleavage - e.g. according to the method of Kemmler et al., J.B.C. (1971), p. 6786 - 6791 and the insulin derivative of formula II purified by known techniques such as chromatography - see e.g. EP-A-0 305 760 - and crystallization.
The preparation of the insulin derivatives of formula II with R2 = Asp and X = His is preferably carried out by hydrolysis of the known basically modified insulin derivatives of formula I in an aqueous acid medium (since only the amide group of asparagine at position A21 needs to be hydrolysed here), preferably at pH values between about 2 and about 4, in particular about 2.5, and at temperatures between about 0 and about 40 °C, preferably at room temperature.
The insulin derivatives of formula II and/or their physiologically compatible salts (such as the alkaline or ammonium salts) according to the invention are mainly used as active substances in a pharmaceutical preparation for the treatment of diabetes mellitus.
The pharmaceutical preparation is preferably a solution or suspension for injection and is characterised by a content of at least one insulin derivative of formula II and/or at least one of its physiologically compatible salts in dissolved, amorphous and/or crystalline, preferably dissolved, form.
The preparation should preferably have a pH between approximately 2,5 and 8,5, in particular between approximately 4,0 and 8,5, contains an appropriate isotonic agent, a suitable preservative and, where appropriate, an appropriate buffer, and preferably a certain concentration of zinc ions, All the ingredients except the active substance form the carrier.
The isotonic agents are e.g. glycerol, glucose, mannite, NaCl, calcium or magnesium compounds such as CaCl2, MgCl2 etc.
The choice of isotonic agent and/or preservative influences the solubility of the insulin derivative or its physiologically compatible salt at the low acid pH.
The use of the product in the final product shall be limited to the following:
For example, sodium acetate, sodium citrate, sodium phosphate, etc. can be used as buffers, especially for setting a pH between about 4.0 and 8.5. Otherwise, physiologically harmless diluted acids (typically HCl) or alkalis (typically NaOH) are also suitable for setting the pH.
If the preparation contains zinc, 1 to 2 mg, in particular 5 to 200 μg zinc/ml, is preferred.
In order to vary the profile of action of the preparation according to the invention, unmodified insulin, preferably bovine, porcine or human insulin, especially human insulin, may also be added.
The preferred concentrations are approximately 1 to 1500, preferably 5 to 1000, and in particular 40 to 400 international units/ml.
The invention is now explained in more detail by the following examples.
A) Genetically engineered production Example 1 Design of a plasmid for the production of Gly (A21) human insulin Arg (B31-OH)
The plasmid pSW3 was described in DE patent application P 38 21 159.9 (HOE 88/F 158). The plasmid DNA is translated with the restriction enzymes Pvu2 and Sal1 and then treated with alkaline bovine phosphatase. The two resulting fragments are separated by gel electrophoresis and the large fragment is isolated. This fragment is linked in a T4 DNA ligase reaction with the following synthetic DNA sequence:
Competent E. coli W3110 cells are transformed by the ligation approach. The transformation mixture is flattened on NA plates containing 20 μg Ap (=ampicillin)/ml and incubated overnight at 37°C. An overnight culture is obtained from individual colonies and extracted from this plasmid DNA. This DNA is characterised by restriction analysis and DNA sequence analysis. Correct plasmids encoding the altered A-chain are given the designation pIK100. The expression is analogous to e.g. 3 of the above-mentioned DE patent application P 38 21 159.9.
Example 2 Design of a plasmid for the production of human insulin Ser ((A21) (Arg B31-OH)
The structure is similar to the path described in the example above, but the synthetic DNA sequence is modified as follows:
The result is the plasmid pIK110, which is characterized by an additional BspH1 recognition sequence.
Example 3 Design of a plasmid for the production of Gly ((A21) -Asn ((B10) -Human Insulin-Arg ((B31-OH)
DNA from the plasmid pIK100 is cleaved with the restriction enzymes Hpal and Dra3 and treated with alkaline bovine phosphatase. The two fragments are separated by gel electrophoresis and the larger of the two fragments is isolated. The resulting plasmid pIK101 is further characterised as described in example 1.
Example 4 Design of a plasmid for the production of Ser ((A21) -Asn ((B10) -human insulin
The design is similar to the cloning described in example 3, but is based on DNA from the plasmid pIK110. The newly designed plasmid is designated pIK111.
Example 5 Design of an expression plasmid for monkey proinsulin
Monkey proinsulin differs from human proinsulin only in that it replaces a single amino acid in the C peptide (B37-Pro instead of Leu in this position of human proinsulin).
The plasmid pSW3 is opened with Hpa1 and Sal1 and the residual plasmid DNA is isolated. From the plasmid pK50 described in EP-A-0 229 998 the Dra3-Sal1-monkeyproinsulin fragment is isolated. The result is the plasmid pSW2, whose DNA is then used as the starting material for the construction of the expression plasmids encoding the di-Arg human insulin derivatives.
Example 6 Design of a plasmid for the production of Gly (A21) human insulin Arg (B31) -Arg (B32) -OH
DNA from the plasmid pSW2 is split with Pvu2 and Sal1 in example 1 and ligated with the synthetic DNA from example 1 to form the plasmid pSW21.
Example 7 Design of a plasmid for the production of Ser ((A21) human insulin-Arg ((B31)-Arg ((B32)-OH)
The plasmid pSW22 is constructed from pSW2 DNA in the same way as in example 2.
Example 8 Design of a plasmid for the production of Gly ((A21) -Asn ((B10) -Human Insulin-Arg ((B31) -Arg ((B32) -OH)
The plasmid pSW23 is constructed from pSW21 DNA in the same way as in example 3.
The following sequence is used as synthetic DNA sequence:
Example 9 Design of a plasmid for the production of Ser ((A21) -Asn ((B10) -human insulin B31 ((Arg) -B32 ((Arg) -OH)
The plasmid pSW24 is constructed from pSW22 DNA using the synthetic DNA sequence described in Example 8 in analogy to Example 4.
(b) Preparation of AspA21-Human Insulin-ArgB31-ArgB32-OH from human insulin-ArgB31-ArgB32-OH by hydrolysis
1 g human insulin ArgB31-ArgB32-OH is slurried in 100 ml H2O. By adding HCl, the pH is set to 2.5 and the solution is left at 37°C. After a week, about half of the material is converted into AspA21 human insulin ArgB31-ArgB32-OH. The product is separated from the starting material by means of an anion exchanger, cut from the eluate in a known way and crystallized in a buffer containing 10,5 g citric acid, 1 g of phenol and 5 ml of a 1% zinc chloride solution at a protein concentration of 5 g/l at pH 6,0. The amount is 390 mg of AspA21H2O31B3H2O3
C) Preparation of a solution for injection
The insulin derivative according to B is dissolved in a sterile carrier solution of the following composition (per ml) at a concentration of 1,4 mg/ml: The test chemical is a mixture of 18 mg glycerol, 10 mg benzyl alcohol, 80 μg Zn2+, pH 4.0.
D) Profile of action of an AspA21 human insulin ArgB31-ArgB32-OH preparation in dogs compared to human insulin ArgB31-ArgB32-OH and basal H insulin Hoechst (R) = an NPH (Hagedorn-neutral protamine) preparation with about 10 μg Zn2+.
This example shows that AspA21-Human Insulin-ArgB31-ArgB32-OH has the same beneficial baseline profile as Human Insulin-ArgB31-ArgB32-OH. In addition, AspA21-Human Insulin-ArgB31-ArgB32-OH has the beneficial property of being long-term stable under the chosen conditions.

Claims (12)

  1. A process for the preparation of an insulin derivative of the formula II in which
    R¹   denotes H or H-Phe,
    R²   denotes a genetically encodable L-amino acid which contains no amide group,
    R³⁰   represents the residue of a neutral genetically encodable L-amino acid,
    R³¹   represents a physiologically acceptable organic radical from the group: amino-(C₂-C₆)-alkoxy, (C₁-C₄)-alkylamino-(C₂-C₆)-alkoxy, di-(C₁-C₄)-alkylamino-(C₂-C₆)-alkoxy, tri-(C₁-C₄)-alkylammonio-(C₂-C₆)-alkoxy, amino-(C₂-C₆)-alkylamino, [(C₁-C₄)-alkylamino]-(C₂-C₆)-alkylamino, di-(C₁-C₄)-alkylamino-(C₂-C₆)-alkylamino or [tri-(C₁-C₄)-alkylamino]-(C₂-C₆)-alkylamino, in particular -O-[CH₂]p-NR₂, -O-[CH₂]p-N⊕R₃, -NH[CH₂]p-NR₂ or -NH-[CH₂]p-N⊕R₃, in which p = 2 to 6 and R is identical or different and is hydrogen or (C₁-C₄)-alkyl, or represents 1 to 3 α-amino acids, whose terminal carboxyl functionality which is present where appropriate can be free, in the form of an ester functionality, an amide functionality, a lactone or reduced to CH₂OH, and
    X   represents a genetically encodable L-amino acid,
    which has an isoelectric point between 5 and 8.5, and the physiologically tolerated salts thereof wherein the expression of a gene structure coding for this insulin derivative is brought about in a host cell, preferably in a bacterium or in a yeast, and - if the gene structure codes for a fusion protein - the respective insulin derivative is liberated from the fusion protein obtained and converted if required into a physiologically tolerated salt.
  2. The process as claimed in claim 1, which comprises preparing an insulin derivative of the formula II in which R¹ represents H-Phe.
  3. The process as claimed in claim 1 or 2, which comprises preparing an insulin derivative of the formula II in which R² represents Gly, Ala, Ser, Thr, Asp or Glu, in particular only Asp.
  4. The process as claimed in one or more of claims 1 to 3, which comprises preparing an insulin derivative of the formula II in which R³⁰ represents Ala, Thr or Ser.
  5. The process as claimed in one or more of claims 1 to 4, which comprises preparing an insulin derivative of the formula II in which R³¹ represents Arg-OH or Arg-Arg-OH.
  6. The process as claimed in one or more of claims 1 to 5, which comprises preparing an insulin derivative of the formula II in which X denotes Asn or Gln.
  7. The process as claimed in one or more of claims 1 to 6, which comprises preparing an insulin derivative of the formula II in which the sequence (A1 to A20) and (B1 to B9, B11 to B29) are the sequence of human, porcine or bovine insulin, in particular the sequence of human insulin.
  8. A process for the preparation of an insulin derivative of the formula II as defined in claim 1, but where
    R²   is only Asp and
    X   is His,
    and of the physiologically tolerated salts of this insulin derivative, which comprises subjecting an insulin derivative of the formula I in which R¹, R³⁰ and R³¹ have the same meaning as in formula II (as defined in claim 1), to hydrolysis in aqueous acidic medium, and converting the insulin derivative of the formula II produced thereby if required into the physiologically tolerated salts thereof.
  9. The use of insulin derivatives of the formula II as defined in claim 1 and of the physiologically tolerated salts of these insulin derivatives as active substances for pharmaceutical compositions for the treatment of diabetes mellitus.
  10. A process for the preparation of a pharmaceutical composition, which comprises converting an effective amount of at least one insulin derivative of the formula II and/or at least one of its physiologically tolerated salts with a physiologically acceptable vehicle and, where appropriate, with further additives and/or auxiliaries into a suitable pharmaceutical presentation.
  11. The process as claimed in claim 10, wherein at least one zinc compound is also added, corresponding to a content of 1 µg to 2 mg, preferably 5 µg to 200 µg, of zinc/ml to the pharmaceutical composition.
  12. The process as claimed in claim 10 or 11, wherein an unmodified insulin, preferably unmodified human insulin, is also added to the pharmaceutical composition.
HK98105250A 1988-11-08 1998-06-12 Insulin derivatives, their use and a pharmaceutical composition containing same HK1006171A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3837825A DE3837825A1 (en) 1988-11-08 1988-11-08 NEW INSULIN DERIVATIVES, THEIR USE AND A PHARMACEUTICAL PREPARATION CONTAINING THEM
DE3837825 1988-11-08

Publications (2)

Publication Number Publication Date
HK1006171B true HK1006171B (en) 1999-02-12
HK1006171A1 HK1006171A1 (en) 1999-02-12

Family

ID=6366698

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98105250A HK1006171A1 (en) 1988-11-08 1998-06-12 Insulin derivatives, their use and a pharmaceutical composition containing same

Country Status (22)

Country Link
US (2) US5656722A (en)
EP (1) EP0368187B1 (en)
JP (1) JP2680145B2 (en)
KR (1) KR0158197B1 (en)
AT (1) ATE93868T1 (en)
AU (1) AU621680B2 (en)
CA (1) CA1339044C (en)
DE (3) DE3837825A1 (en)
DK (1) DK173196B1 (en)
ES (1) ES2059676T4 (en)
FI (1) FI100185B (en)
HK (1) HK1006171A1 (en)
HU (2) HU213018B (en)
IE (1) IE63338B1 (en)
IL (1) IL92222A (en)
LU (1) LU90614I2 (en)
NL (1) NL300019I2 (en)
NO (2) NO177963C (en)
NZ (1) NZ231272A (en)
PH (1) PH30695A (en)
PT (1) PT92220B (en)
ZA (1) ZA898456B (en)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2099193T3 (en) * 1991-12-18 1997-05-16 Hoechst Ag PROCEDURE FOR OBTAINING SOLUTIONS WITH INSULIN CONTENT.
EP0622376B1 (en) * 1993-04-27 2001-08-08 Hoechst Aktiengesellschaft Amorphous monospheric forms of insulin derivatives
DE19512484A1 (en) 1995-04-04 1996-10-17 Bayer Ag Carbohydrate modified cytostatics
ES2218622T3 (en) * 1996-07-26 2004-11-16 Aventis Pharma Deutschland Gmbh INSULIN DERIVATIVES WITH INCREASED ZINC UNION ACTIVITY.
DE19652713C2 (en) * 1996-12-18 2001-11-22 Aventis Pharma Gmbh Process for the purification of insulin and insulin derivatives by chromatography on a strongly acidic cation exchanger
PL340255A1 (en) * 1997-10-24 2001-01-29 Lilly Co Eli Non-dissolving insulin compositions
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
DE19825447A1 (en) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh New insulin analogues with increased zinc formation
DE19838097A1 (en) 1998-08-24 2000-03-02 Hoechst Marion Roussel De Gmbh Process for the chromatographic purification of insulins
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
DK1265630T3 (en) * 2000-03-24 2006-10-09 Genentech Inc Use of insulin for the treatment of cartilage disease
US7316999B2 (en) 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
DE10114178A1 (en) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinc-free and low-zinc insulin preparations with improved stability
FR2822834B1 (en) * 2001-04-02 2005-02-25 Flamel Tech Sa COLLOIDAL SUSPENSION OF NANOPARTICLES BASED ON AMPHIPHILIC COPOLYMERS FOR VECTORIZATION OF ACTIVE INGREDIENTS AND THEIR METHOD OF PREPARATION
MXPA04001560A (en) * 2001-08-28 2004-05-17 Lilly Co Eli Pre-mixes of glp-1 and basal insulin.
JP4563675B2 (en) 2001-10-12 2010-10-13 ハイ・ポイント・ファーマスーティカルズ、エルエルシー Substituted piperidines and their use for the treatment of histamine H3 receptor related diseases
JP2005508360A (en) * 2001-10-19 2005-03-31 イーライ・リリー・アンド・カンパニー GLP-1 and insulin biphasic mixture
HUP0700126A2 (en) * 2001-12-20 2007-06-28 Lilly Co Eli Insulin molecule having protracted time action
US7774816B2 (en) * 2002-04-23 2010-08-10 Rovi Technologies Corporation Conflict manager for a video recorder
DE10227232A1 (en) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Sour insulin preparations with improved stability
FR2843117B1 (en) * 2002-07-30 2004-10-15 Flamel Tech Sa POLYAMINOACIDS FUNCTIONALIZED BY AT LEAST ONE HYDROPHOBIC GROUP AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
ATE482747T1 (en) 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc NEW AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USES
WO2004096854A2 (en) * 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
FR2860516B1 (en) * 2003-10-03 2006-01-13 Flamel Tech Sa TELECHELIC HOMOPOLYAMINOACIDES FUNCTIONALIZED BY HYDROPHOBIC GROUPS AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
CN113304250A (en) 2003-11-20 2021-08-27 诺和诺德股份有限公司 Propylene glycol-containing peptide formulations optimized for production and use in injection devices
FR2862536B1 (en) * 2003-11-21 2007-11-23 Flamel Tech Sa PHARMACEUTICAL FORMULATIONS FOR THE PROLONGED DELIVERY OF ACTIVE (S) PRINCIPLE (S) AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
FR2873040B1 (en) * 2004-07-19 2007-11-30 Flamel Technologies Sa COLLOIDAL FORMULATION OF LONG-ACTING INSULIN AND ITS PREPARATION
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP2233470B1 (en) 2005-07-04 2011-12-07 High Point Pharmaceuticals, LLC Histamine H3 receptor antagonists
ES2426345T3 (en) 2005-07-20 2013-10-22 Eli Lilly And Company Compound bound in 1-amino position
CA2629223C (en) 2005-11-17 2013-08-06 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
FR2896164B1 (en) * 2006-01-18 2008-07-04 Flamel Technologies Sa COLLOIDAL FORMULATION OF LONG-ACTING INSULIN AND ITS PREPARATION
EP1996224B1 (en) 2006-03-15 2012-11-07 Novo Nordisk A/S Mixtures of amylin and insulin
SG170785A1 (en) 2006-03-28 2011-05-30 Transtech Pharma Benzothiazoles having histamine h3 receptor activity
CA2649111C (en) 2006-04-24 2013-09-10 Eli Lilly And Company Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
PT2079732E (en) 2006-05-29 2012-02-02 High Point Pharmaceuticals Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
DE102006031955A1 (en) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Process for the preparation of dibasic B chain end insulin analogs
DE102006031962A1 (en) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidated insulin glargine
US7417517B2 (en) * 2006-07-13 2008-08-26 Motorola, Inc. Method and apparatus for a communications filter
EP2514406A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
RU2472492C2 (en) 2007-06-01 2013-01-20 Ново Нордиск А/С Stable non-aqueous pharmaceutical compositions
EP2178909B1 (en) 2007-08-13 2015-10-21 Novo Nordisk A/S Rapid acting insulin analogues
PT2597103T (en) 2007-11-16 2017-02-08 Novo Nordisk As Stable pharmaceutical compositions comprising liraglutide and degludec
DE102008025008A1 (en) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Insulin analogs which comprise A chain and B chain with disulfide bonds for use in treatment of diabetes
DE102008003566A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh New insulin analogs useful for treating diabetes
DE102008025007A1 (en) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Insulin analogs which comprise A chain and B chain with disulfide bonds for use in treatment of diabetes and for cartilage regeneration
DE102008003568A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh New insulin analogs useful for treating diabetes
WO2009087082A2 (en) * 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
WO2009087081A2 (en) * 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
PL219335B1 (en) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków New slow-release insulin analogues
DE102008053048A1 (en) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
DE102008051834A1 (en) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Drug, useful e.g. for treating diabetes, preferably type-I or II and for controlling fasting, postprandial and/or postabsorptive plasma glucose concentration, comprises insulin and glucagon-like peptide-1 agonist
DE102009038210A1 (en) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1 agonist
DK2349324T3 (en) 2008-10-17 2017-12-11 Sanofi Aventis Deutschland COMBINATION OF AN INSULIN AND A GLP-1 AGONIST
EP2362730A4 (en) 2008-11-21 2012-08-29 High Point Pharmaceuticals Llc Adamantyl benzamide compounds
JP2012532177A (en) * 2009-07-06 2012-12-13 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Thermal and vibration stable insulin formulations
EP2451471A1 (en) * 2009-07-06 2012-05-16 Sanofi-Aventis Deutschland GmbH Slow-acting insulin preparations
PH12011502708B1 (en) 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
SG178195A1 (en) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Long acting insulin composition
CN102548583B (en) 2009-07-31 2015-04-22 赛诺菲-安万特德国有限公司 Prodrugs comprising an insulin linker conjugate
KR101836070B1 (en) 2009-11-13 2018-03-09 사노피-아벤티스 도이칠란트 게엠베하 Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine
ES2965209T3 (en) 2009-11-13 2024-04-11 Sanofi Aventis Deutschland Pharmaceutical composition comprising desPro36exendin-4(1-39)-Lys6-NH2 and methionine
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
CN103179978A (en) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
PH12013501495A1 (en) 2011-01-20 2013-09-16 Zealand Pharma As Combination of acylated glucagon analogues with insulin analogues
US10130684B2 (en) 2011-02-03 2018-11-20 Pharmedica Ltd. Oral dissolving films for insulin administration, for treating diabetes
CN102219851B (en) 2011-05-09 2012-05-30 甘李药业有限公司 Preparation method for insulin glargine crystals
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CA2843586A1 (en) 2011-08-10 2013-02-14 Adocia Injectable solution of at least one type of basal insulin
ES2550357T3 (en) 2011-08-29 2015-11-06 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in type 2 diabetes patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013063277A1 (en) 2011-10-25 2013-05-02 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US10350139B2 (en) 2011-10-25 2019-07-16 Corning Incorporated Pharmaceutical glass packaging assuring pharmaceutical sterility
CN104114155B (en) 2012-01-09 2019-02-15 阿道恰公司 An injectable solution with a pH of 7 and containing at least a basal insulin with a PI of 5.8 to 8.5 and a substituted copoly(amino acid)
PL222975B1 (en) 2012-05-23 2016-09-30 Inst Biotechnologii I Antybiotyków Insulin analog or a pharmaceutically tolerated salt thereof, a pharmaceutical composition of prolonged therapeutic use of insulin analog, dosage and method for treatment of diabetes
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
HRP20170673T1 (en) 2012-06-04 2017-07-14 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
FR3001896B1 (en) 2013-02-12 2015-07-03 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISO-ELECTRIC POINT IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIC ANIONIC POLYMER
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
FR3001895B1 (en) 2013-02-12 2015-07-03 Adocia PH7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISOELECTRIC POINT IS INCLUDED IN 5.8 AND 8.5 AND AN ANIONIC COMPOUND CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS
NZ707160A (en) * 2012-12-19 2016-08-26 Wockhardt Ltd A stable aqueous composition comprising human insulin or an analogue or derivative thereof
TWI780236B (en) 2013-02-04 2022-10-11 法商賽諾菲公司 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
UA117480C2 (en) 2013-04-03 2018-08-10 Санофі Treatment of diabetes mellitus by long–acting formulations of insulins
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9713572B2 (en) 2013-04-24 2017-07-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707153B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707155B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717649B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717648B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
MX2016008979A (en) 2014-01-09 2016-10-04 Sanofi Sa Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives.
BR112016013832A2 (en) 2014-01-09 2017-08-08 Sanofi Sa USE OF INSULIN ANALOG AND/OR DERIVATIVE, PHARMACEUTICAL FORMULATION AND PROCESS FOR THE PREPARATION OF THE SAME, KIT AND MEDICAL DEVICE
CN114939156A (en) 2014-01-09 2022-08-26 赛诺菲 Stabilized pharmaceutical formulations of insulin aspart
HRP20230470T1 (en) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
CN104688677B (en) * 2015-02-05 2018-02-09 通化东宝药业股份有限公司 A kind of insulin glargine injecta of stabilization and preparation method thereof
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
AR107560A1 (en) 2016-02-24 2018-05-09 Lilly Co Eli COMPOUND THAT DECREASES GLUCOSE IN BLOOD
FR3052072A1 (en) 2016-06-07 2017-12-08 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACIDE CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
EP4129321B1 (en) 2016-12-05 2025-10-15 Nuritas Limited Compositions comprising peptide wkdeagkplvk
EP3592377A4 (en) 2017-03-09 2021-02-17 Diamedica Inc. DOSAGE FORMS OF TISSUE KALLIKREIN 1
FR3070264A1 (en) 2017-08-24 2019-03-01 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN INCLUDING AN INHIBIT OF 5.8 TO 8.5 AND A CO-POLYAMINOACIDE CARBOXYLATE AND HYDROPHOBIC RADICAL CARRIERS
WO2019110625A1 (en) 2017-12-06 2019-06-13 Adocia Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
FR3083089A1 (en) 2018-06-29 2020-01-03 Adocia PH 7 INJECTION SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACID CARRYING CARBOXYLATES AND HYDROPHOBIC RADICALS
FR3083088B1 (en) 2018-06-29 2020-10-02 Adocia SOLUTION FOR INJECTION AT PH 7 INCLUDING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACID CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS
KR20240171197A (en) 2017-12-07 2024-12-06 아도시아 Injectable pH 7 solution comprising at least one basal insulin having a pI from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4671300A2 (en) 2017-12-07 2025-12-31 Adocia Injectable solution with pH 7 containing at least one basal insulin with a pi between 5.8 and 8.5 and a co-polyaminic acid with carboxylate and hydrophobic radicals.
BR112020011570A2 (en) 2017-12-07 2020-12-08 Adocia SOLUTION INJECTABLE AT A PH 7 UNDERSTANDING AT LEAST A BASAL INSULIN PRESENTING A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINO ACID CONTAINING CARBOXYLATE AND HYDROPHOBIC RADICAL LOADS
US20210214412A1 (en) * 2018-04-16 2021-07-15 University Of Utah Research Foundation Glucose-responsive insulin
WO2019243628A1 (en) 2018-06-22 2019-12-26 Adocia Injectable composition with a ph of 7 comprising a co-polyaminoacid bearing carboxylate charges and hydrophobic radicals and at least one basal insulin having at least a prandial effect and a basal effect
FR3084585B1 (en) 2018-08-03 2020-11-06 Adocia SOLUTION FOR INJECTION AT PH 7 INCLUDING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 AND AN AMPHIPHILIC COMPOUND CARRIER OF HYDROPHOBIC RADICALS
KR102666154B1 (en) 2018-08-08 2024-05-20 주식회사 대웅제약 Long-acting Insulin Analog and Derivatives Thereof
US20200179489A1 (en) 2018-12-07 2020-06-11 Adocia Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol
WO2020115334A1 (en) 2018-12-07 2020-06-11 Adocia Method for preparing a stable composition in the form of an injectable aqueous solution
KR20200080747A (en) 2018-12-27 2020-07-07 주식회사 폴루스 An Enzymatic Conversion Composition for Producing Insulin from Proinsulin and a Method for Producing Insulin from Proinsulin Using the Same
KR20200080748A (en) 2018-12-27 2020-07-07 주식회사 폴루스 A Method for Purifying Proinsulin Using Anion Exchange Chromatography
KR20200082618A (en) 2018-12-31 2020-07-08 주식회사 폴루스 Ramp Tag for Overexpressing Insulin and Method for Producing Insulin Using the Same
WO2020245470A1 (en) 2019-06-07 2020-12-10 Adocia Injectable solution at ph 7 containing at least one basal insulin, the pi of which is between 5.8 and 8.5, liraglutide, and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
TW202434620A (en) 2019-07-31 2024-09-01 美商美國禮來大藥廠 Relaxin analogs and methods of using the same
CN113105536B (en) 2020-09-11 2023-07-18 美药星（南京）制药有限公司 New proinsulin glargine and method for preparing insulin glargine by using same
CN114805610B (en) * 2022-06-23 2022-10-04 北京惠之衡生物科技有限公司 Recombinant genetic engineering bacterium for highly expressing insulin glargine precursor and construction method thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3033127A1 (en) * 1980-09-03 1982-04-08 Hoechst Ag, 6000 Frankfurt NEW INSULIN ANALOG
DE3326473A1 (en) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt PHARMACEUTICAL AGENT FOR TREATING THE DIABETES MELLITUS
DE3326472A1 (en) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt NEW INSULIN DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AND PHARMACEUTICAL AGENTS FOR TREATING THE DIABETES MELLITUS
DE3327709A1 (en) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt INSULIN DERIVATIVE CRYSTAL SUSPENSIONS, METHOD FOR THE PRODUCTION AND USE THEREOF
DK347086D0 (en) * 1986-07-21 1986-07-21 Novo Industri As NOVEL PEPTIDES
DK113585D0 (en) * 1985-03-12 1985-03-12 Novo Industri As NEW PEPTIDES
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
AU612141B2 (en) * 1987-02-25 1991-07-04 Novo Nordisk A/S Novel insulin derivatives

Similar Documents

Publication Publication Date Title
HK1006171B (en) Insulin derivatives, their use and a pharmaceutical composition containing same
HK1006171A1 (en) Insulin derivatives, their use and a pharmaceutical composition containing same
AU615760B2 (en) Insulin analogues
US5008241A (en) Novel insulin peptides
US4946828A (en) Novel insulin peptides
US4608364A (en) Pharmaceutical agent for the treatment of diabetes mellitus
US6221837B1 (en) Insulin derivatives with increased zinc binding
AU612141B2 (en) Novel insulin derivatives
US5506202A (en) Insulin derivatives, a process for the preparation thereof, the use thereof, and a pharmaceutical formulation containing them
EP0216832B1 (en) Novel insulin derivatives and pharmaceutical preparations containing these derivatives
US5430016A (en) Insulin compounds and compositions
Markussen et al. Soluble, prolonged-acting insulin derivatives. I. Degree of protraction and crystallizability of insulins substituted in the termini of the B-chain
CA1246478A (en) Process for the preparation of insulin derivatives, the b chain of which is lengthened c-terminally, novel insulin derivatives modified by bases, agents containing these derivatives and their use
CA2006578A1 (en) Human insulin analogues
NO170978B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF NEW PEPTIDES
IE912247A1 (en) Novel, protracted insulin analogues
CA2215694A1 (en) Insulin derivatives
JP3131215B2 (en) New insulin derivative
CA2330183C (en) Novel insulin analogs with enhanced zinc binding
MXPA97005667A (en) Insulin derivatives with zinc increment